Dipeptidyl peptidase-4 inhibitors: Comparative analysis of members of the group
https://doi.org/10.14341/probl201258161-66
Abstract
References
1. Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004; 53: 2181-2189.
2. Deacon C.F., Nauck M.A., Toft-Nielsen M. et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-1131.
3. Deacon C.F., Hughes T.E., Holst J.J. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 1998; 47: 764-769.
4. Ahrén B., Simonsson E., Larsson H. et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002; 25: 869-875.
5. Brandt I., Joossens J., Chen X. et al. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). Biochem Pharmacol 2005; 70: 134-143.
6. Burkey B.F., Russell M., Wang K. et al. Vildagliptin displays slow tight-binding to dipeptidyl peptidase (DPP)-4, but not DPP-8 or DPP-9 (Abstract 0788). Diabetologia 2006; 49: Suppl 1: 477.
7. Kim Y.B., Kopcho L.M., Kirby M.S. et al. Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118). Arch Biochem Biophys 2006; 445: 9-18.
8. He Y.L., Wang Y., Bullock J.M. et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 2007; 47: 633-641.
9. Boulton D.W., Geraldes M. Safety, tolerability, pharmacokinetics and pharmacodynamics of once daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects (Poster 0606-P). Diabetes 2007; 56: Suppl 1: A161.
10. Bergman A.J., Stevens C., Zhou Y. et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006; 28: 55-72.
11. Lankas G.R., Leiting B., Roy R.S. et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005; 54: 2988-2994.
12. Reinhold D., Goihl A., Wrenger S. et al. Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice. Clin Chem Lab Med 2009; 47: 268-274.
13. Kim D., Wang L., Beconi M. et al. (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48: 141-151.
14. Feng J., Zhang Z., Wallace M.B. et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007; 50: 2297-2300.
15. Burkey B.F., Hoffmann P.K., Hassiepen U. et al. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab 2008; 10: 1057-1061.
16. Kirby M.S., Dorso C., Wang A. et al. In vitro enzymologic characteristics of saxagliptin, a highly potent and selective DPP4 inhibitor with "slow binding" characteristic (Abstract). Clin Chem Lab Med 2008; 46: A79.
17. European Medicines Agency (EMEA). Galvus (vildagliptin)-European public assessment report (EPAR)-scientific discussion. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/galvus/H-771-en6.pdf. Accessed 5 July 2010.
18. European Medicines Agency (EMEA). Onglyza (saxagliptin)-European public assessment report (EPAR)-CHMP Assessment Report. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/onglyza/H-1039-en6.pdf. Accessed 5 July
19. Herman G.A., Stein P.P., Thornberry N.A., Wagner J.A. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther 2007; 81: 761-767.
20. He Y.L., Sadler B.M., Sabo R. et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007; 46: 787-802.
21. Fura A., Khanna A., Vyas V. et al. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos 2009; 37: 1164-1171.
22. He H., Tran P., Yin H. et al. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dis 2009; 37: 536-544.
23. Onglyza prescribing information. Available from URL: http://packageinserts.bms.com/pi/pi_onglyza.pdf. Accessed 5 July 2010.
24. Bergman A.J., Cote J., Yi B. et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007; 30: 1862-1864.
25. Herman G., Hanefeld M., Wu M. et al. Effect of MK-0431,a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes. Diabetes 2005; 54: Suppl 1: A134: Abstract 541.
26. Medicalnewstoday.com. Sitagliptin (MK-0431) for Type 2 Diabetes shows promise in Phase II clinical trials. 11 June 2005. Available from URL: http://medicalnewstoday.com/medicalnews.php?newsid= 25962. Accessed August 24, 2006.
27. Dejager S., Razac S., Foley J.E. et al. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007; 39: 3: 218-223.
28. Rosenstock J., Sankoh S., List J.F. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008; 10: 5: 376-86.
29. Karasik A., Charbonnel B., Liu J. et al. Sitagliptin added to ongoing metformin therapy enhanced glycemic control and beta-cell function in patients with type 2 diabetes. Diabetes 2006; 55: A119: Abstract 501.
30. Hermansen K., Kipnes M., Luo E., Fanurik D. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 5: 733-745.
31. Garber A., Camisasca R.P., Ehrsam E. et al. Vildagliptin addedto metformin improves glycemic control and may mitigate metformin-induced GI side effects in patients with type 2 diabetes (T2DM). Diabetes 2006; 55: Suppl 1: A29: Abstract 121-OR.
32. Derosa G., Maffioli P., Ferrare I. et al. Effects of One Year Treatment of Vildagliptin Added to Pioglitazone or Glimepiride in Poorly Controlled Type 2 Diabetic Patients. Horm Metab Res 2010; 42: 663-669.
33. Fonseca V., Dejager S., Albrecht D. et al. Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM). Diabetes 2006; 55: Suppl 1: A111: Abstract 467.
34. Scheen A.J., Charpentier G., Ostgren C.J. et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010; 26: 540-549.
35. Monami M., Iacomelli I., Marchionni N. et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010; 20: 224-235.
36. Marfella R., Barbieri M., Grella R. et al. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications 2010; 24: 2: 79-83.
37. Cox M.E., Rowell J., Corsino L. et al. Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug Healthcare Patient Saf 2010; 2: 7-19.
38. Rosenstock J., Foley J.E., Rendell M. et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008; 31: 30-35.
39. Meece J. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. Cur Med Res Opin 2007; 23: 933-944.
40. Gerich J. DPP-4 inhibitors: What may be the clinical differentiators? Diabet Res Clin Pract 2010; 90: 131-140.
41. Elashoff M., Matveyenko A.V., Gier B. et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1 - based therapies. Gastroenterology 2011; 141: 150-156.
42. Ligueros-Saylan M., Foley J.E., Schweizer A. et al. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of phase II and III clinical trials. Diabetes Obes Metab 2010; 12: 495-509.
Review
For citations:
Shestakova E.A., Galstian G.R. Dipeptidyl peptidase-4 inhibitors: Comparative analysis of members of the group. Problems of Endocrinology. 2012;58(1):61-66. https://doi.org/10.14341/probl201258161-66
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
